Phosphodiesterase function and regulation

BACKGROUND: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. METHODS: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary ar…

• BAHRİ AKDENİZ

Özet henüz yok.

• BÜLENT GÜMÜŞEL

Özet henüz yok.

• HİLMİ BURAK KANDİLCİ

Özet henüz yok.

• ZEYNEP PINAR ÖNEN

Özet henüz yok.

• NİGAR GÜLFER OKUMUŞ
• ZEYNEP PINAR ÖNEN

OBJECTIVES: Although cognitive impairment is recognized as an important clinical feature of bipolar disorder, there is no standard cognitive battery that has been developed for use in bipolar disorder research. The aims of this paper were to identify the cognitive measures from the literature that show the greatest ma…

• ÖMER AYDEMİR

Özet henüz yok.

We have isolated and characterized complete cDNAs for two isoforms (HSPDE4D4 and HSPDE4A5) encoded by the human PDE4D gene, one of four genes that encode cAMP-specific rolipram-inhibited 3',5'-cyclic nucleotide phosphodiesterases (type IVPDEs; PDE4 family). The HSPDE4D4 and HSPDE4D5 cDNAs encode proteins of 810 and 74…

BACKGROUND: Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the progression of idiopathic pulmonary fibrosis, but an assessment of its effects in other types of progressive pulmon…

• ÖZLEM ÖZDEMİR KUMBASAR

BACKGROUND: Although bipolar disorder and schizophrenia have long been viewed as distinct illnesses, there is growing evidence that these two complex diseases share some common genes, which may manifest as overlapping neuropsychological impairments. Although working memory dysfunction has been proposed to be central t…

• SİBEL ÇAKIR

Özet henüz yok.

• ZEYNEP PINAR ÖNEN

Özet henüz yok.

• NESRİN MOĞULKOÇ BISHOP